中期年龄相关性黄斑变性多模式视觉缺陷参考图:对比敏感度与低对比度视力
该前瞻性横断面研究纳入509只眼,涵盖非渗出性AMD各阶段及健康对照,建立对比敏感度和低对比度视力的参考限值。研究发现AULCSF在早期AMD下降2.2 dB、中期3.7 dB、晚期8 dB,中期AMD中50%眼AULCSF超出参考限值,结构生物标志物风险评分与AULCSF及低频CS显著相关。
要点
- AULCSF在早期AMD下降2.2 dB,中期3.7 dB,晚期8 dB。
- 中期AMD中50%眼AULCSF超出参考限值,39%眼LCVA超出。
- 风险评分与AULCSF及1-3 cpd CS显著相关,与BCVA和LCVA无关。
核心结论
- AMD结构生物标志物的功能后果通过结构-功能分析得到验证。
- 提供的对比敏感度和低对比度视力多模式视觉缺陷参考图可用于临床随访AMD视力丧失进展及作为临床试验终点。
研究设计与样本
- 前瞻性横断面研究,纳入509只眼(358名受试者):317只干性AMD眼(早期99只、中期177只、晚期41只),192只健康对照眼。
- 参考限值由对照眼的最佳矫正视力、定量对比敏感度函数测量的低对比度视力、对数CSF曲线下面积及多频率对比敏感度定义。
- 风险评分由每只眼结构生物标志物总和定义,采用多元线性回归分析其与AMD各阶段视觉结局的关联。
主要发现
- 与对照相比,AULCSF在早期AMD下降2.2 dB,中期AMD下降3.7 dB,晚期AMD下降8 dB。
- 中期AMD眼超出参考限值的比例:AULCSF为50%,BCVA为36%,LCVA为39%。
- 在早期和中期AMD中,风险评分与AULCSF(p<0.02)及低频(1-3 cpd)对比敏感度(p<0.005)显著相关,但与BCVA和LCVA无关(p>0.05)。
- 高风险眼超出1-3 cpd参考限值的比例(60-68%)高于低风险眼(24-30%)。
- AULCSF和LCVA缺陷展示于新型多模式视力丧失图上。
关键数值与推荐
- AULCSF下降:早期AMD 2.2 dB,中期AMD 3.7 dB,晚期AMD 8 dB。
- 中期AMD超出参考限值比例:AULCSF 50%,BCVA 36%,LCVA 39%。
- 风险评分与AULCSF相关p<0.02,与1-3 cpd CS相关p<0.005,与BCVA和LCVA无关p>0.05。
- 高风险眼超出1-3 cpd参考限值比例60-68%,低风险眼24-30%。
临床怎么用
- 对比敏感度和低对比度视力参考图可用于常规临床实践中随访AMD视力丧失进展。
- 该参考图可作为AMD临床试验的功能性终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide a reference map of deficits in contrast sensitivity (CS) and low-contrast visual acuity (LCVA) across stages of non-exudative age-related macular degeneration (AMD) and evaluate functional consequences of optical coherence tomography structural biomarkers. METHOD: Prospective cross-sectional study of 509 eyes of 358 subjects: 317 dry AMD eyes (99 early, 177 intermediate, 41 advanced), 192 healthy control eyes. Reference limits defined from control eye measures of best-corrected visual acuity (BCVA), quantitative contrast sensitivity function (CSF) measures of LCVA, area under the logarithm CSF (AULCSF), CS at multiple frequencies. Risk scores defined by the sum of structural biomarkers in each eye were associated with visual outcomes across and within AMD stages using multiple linear regression analyses. RESULTS: Compared with controls, AULCSF declined by 2.2 decibels (dB) in early AMD (eAMD), 3.7 dB in intermediate AMD (iAMD) and 8 dB in advanced AMD. Proportions iAMD eyes breaching reference limits: 50% for AULCSF, 36% for BCVA, 39% for LCVA. For eAMD and iAMD, risk scores were significantly correlated with AULCSF (p<0.02) and CS at low frequencies (1-3 cpd, p<0.005) but not BCVA and LCVA (p>0.05). High-risk eyes breached 1-3 cpd reference limits at higher rates (60-68%) than low-risk eyes (24-30%). AULCSF and LCVA deficits were presented on a novel map of multimodal vision loss. CONCLUSION: The functional consequences of AMD structural biomarkers were validated by structure-function analyses. We provide a reference map of multimodal vision deficits in AMD for CS and LCVA that could be useful to follow the progression of vision loss in AMD in routine clinical practice and as a clinical trial endpoint.
引用
- Vingopoulos F, Katz R, Patel NS, et al. Reference map of multimodal vision deficits in intermediate age-related macular degeneration: contrast sensitivity and low-contrast visual acuity. Br J Ophthalmol. 2026. PMID: 42386395. doi:10.1136/bjo-2025-329091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。